TAK-285 Size:Solid 10 mg Saint-Geniez M

Saint-Geniez M

Selective inhibition of JNK by CC-930 exerted potent antifibrotic effects in vitro and in different models in vivo

71(15):5057-61

Dainichi T

54(4):352-4

TAK-285 Size:Solid 10 mg Saint-Geniez MTAK 285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK 285 is currently being developed by Takeda. TAK 285 was found to be well tolerate in Phase I trials. Absorption of TAK 285 was rapid after oral dosing, and plasma exposure at steady state increased in a dose proportional fashion for doses ranging from 50 to 300 mg b. i. d. A partial response was observed